◀ Back to MYD88

CD14 — MYD88

Pathways - manually collected, often from reviews:

• BioCarta toll-like receptor pathway: TLR2/TLR6 activating compounds/TLR2/TLR6/MYD88/IRAK/CD14 complex (CD14-TLR6-TLR2-MYD88-IRAK1) → TRAF6 (modification, activates)
• BioCarta toll-like receptor pathway: CD14 → LPS/TLR4/TLR4/TIRAP/TOLLIP/PKR/MYD88/IRAK/MD-2/CD14 complex (EIF2AK2-MYD88-CD14-TLR4-TOLLIP-TIRAP-IRAK1-LY96) (modification, collaborate)
  
• BioCarta toll-like receptor pathway: CD14 → TLR4/TLR4/TIRAP/TOLLIP/MYD88/IRAK/PKR/MD-2 complex (IRAK1-LY96-TIRAP-TLR4-TOLLIP-MYD88-EIF2AK2) (modification, collaborate)
  
• BioCarta toll-like receptor pathway: None → LPS/TLR4/TLR4/TIRAP/TOLLIP/PKR/MYD88/IRAK/MD-2/CD14 complex (EIF2AK2-MYD88-CD14-TLR4-TOLLIP-TIRAP-IRAK1-LY96) (modification, collaborate)
  
• BioCarta toll-like receptor pathway: LPS/TLR4/TLR4/TIRAP/TOLLIP/PKR/MYD88/IRAK/MD-2/CD14 complex (EIF2AK2-MYD88-CD14-TLR4-TOLLIP-TIRAP-IRAK1-LY96) → TLR4/TLR4/TIRAP/TOLLIP/MYD88/IRAK/PKR/MD-2 complex (IRAK1-LY96-TIRAP-TLR4-TOLLIP-MYD88-EIF2AK2) (modification, collaborate)
  
• BioCarta inactivation of gsk3 by akt causes accumulation of b-catenin in alveolar macrophages: LPS/TLR4/TLR4/TIRAP/TOLLIP/MYD88/IRAK/PKR/MD-2/CD14/LBP complex (IRAK1-LY96-TIRAP-TLR4-TOLLIP-MYD88-EIF2AK2-EHHADH-CD14) (modification, collaborate)
• BioCarta inactivation of gsk3 by akt causes accumulation of b-catenin in alveolar macrophages: LPS/TLR4/TLR4/TIRAP/TOLLIP/MYD88/IRAK/PKR/MD-2/CD14/LBP complex (IRAK1-LY96-TIRAP-TLR4-TOLLIP-MYD88-EIF2AK2-EHHADH-CD14) → CD14/LBP complex (CD14-EHHADH) (modification, collaborate)
  
• BioCarta inactivation of gsk3 by akt causes accumulation of b-catenin in alveolar macrophages: LPS/TLR4/TLR4/TIRAP/TOLLIP/MYD88/IRAK/PKR/MD-2/CD14/LBP complex (IRAK1-LY96-TIRAP-TLR4-TOLLIP-MYD88-EIF2AK2-EHHADH-CD14) → TLR4/TLR4/TIRAP/TOLLIP/MYD88/IRAK/PKR/MD-2 complex (IRAK1-LY96-TIRAP-TLR4-TOLLIP-MYD88-EIF2AK2) (modification, collaborate)
  
• BioCarta inactivation of gsk3 by akt causes accumulation of b-catenin in alveolar macrophages: CD14/LBP complex (CD14-EHHADH) → TLR4/TLR4/TIRAP/TOLLIP/MYD88/IRAK/PKR/MD-2 complex (IRAK1-LY96-TIRAP-TLR4-TOLLIP-MYD88-EIF2AK2) (modification, collaborate)
  
• BioCarta toll-like receptor pathway: TLR2/TLR6 activating compounds/TLR2/TLR2/MYD88/IRAK/CD14 complex (MYD88-IRAK1-CD14-TLR2) → TRAF6 (modification, activates)
• BioCarta toll-like receptor pathway: CD14 → TLR2/TLR6 activating compounds/TLR2/TLR6/MYD88/IRAK/CD14 complex (CD14-TLR6-TLR2-MYD88-IRAK1) (modification, collaborate)
  
• BioCarta toll-like receptor pathway: CD14 → TLR2/TLR6/MYD88/IRAK complex (IRAK1-MYD88-TLR6-TLR2) (modification, collaborate)
  
• BioCarta toll-like receptor pathway: TLR2/TLR6 activating compounds/TLR2/TLR6/MYD88/IRAK/CD14 complex (CD14-TLR6-TLR2-MYD88-IRAK1) → TLR2/TLR6/MYD88/IRAK complex (IRAK1-MYD88-TLR6-TLR2) (modification, collaborate)
  
• BioCarta inactivation of gsk3 by akt causes accumulation of b-catenin in alveolar macrophages: LPS/TLR4/TLR4/TIRAP/TOLLIP/MYD88/IRAK/PKR/MD-2/CD14/LBP complex (IRAK1-LY96-TIRAP-TLR4-TOLLIP-MYD88-EIF2AK2-EHHADH-CD14) (ceramide biosynthetic process, activates)
• BioCarta toll-like receptor pathway: LPS/TLR4/TLR4/TIRAP/TOLLIP/PKR/MYD88/IRAK/MD-2/CD14 complex (EIF2AK2-MYD88-CD14-TLR4-TOLLIP-TIRAP-IRAK1-LY96) → TRAF6 (modification, activates)
• BioCarta toll-like receptor pathway: CD14 → TLR2/TLR6 activating compounds/TLR2/TLR2/MYD88/IRAK/CD14 complex (MYD88-IRAK1-CD14-TLR2) (modification, collaborate)
  
• BioCarta toll-like receptor pathway: CD14 → TLR2/TLR2/MYD88/IRAK complex (MYD88-IRAK1-TLR2) (modification, collaborate)
  
• BioCarta toll-like receptor pathway: TLR2/TLR6 activating compounds/TLR2/TLR2/MYD88/IRAK/CD14 complex (MYD88-IRAK1-CD14-TLR2) → TLR2/TLR2/MYD88/IRAK complex (MYD88-IRAK1-TLR2) (modification, collaborate)
  
• Reactome Reaction: CD14 → MYD88 (reaction) Li et al., Proc Natl Acad Sci U S A 2002, Yamamoto et al., Nature 2002, Horng et al., Nature 2002, Kollewe et al., J Biol Chem 2004, Cheng et al., Biochem Biophys Res Commun 2007, Kawagoe et al., J Exp Med 2007, Kawagoe et al., Nat Immunol 2008, Motshwene et al., J Biol Chem 2009, Lin et al., Nature 2010, George et al., J Biol Chem 2011, Wesche et al., Immunity 1997
• Reactome Reaction: CD14 → MYD88 (indirect_complex) Yamamoto et al., Nature 2002, Horng et al., Nature 2002, Motshwene et al., J Biol Chem 2009, Lin et al., Nature 2010, George et al., J Biol Chem 2011, Wesche et al., Immunity 1997

Text-mined interactions from Literome

Oshikawa et al., Biochem Biophys Res Commun 2003 (Lung Diseases) : The results demonstrated three patterns of gene expression : the TLR2 and myeloid differentiation factor 88 ( MyD88 ) gene expressions were induced in AM in response to lipopolysaccharide (LPS), interleukin (IL)-1beta, or tumor necrosis factor-alpha or in the lung tissue of an LPS induced acute lung injury model ; the gene expressions of TLR1, -3, -6, CD14 , and MD2 were unchanged ; and the TLR4 and TLR5 gene expressions were downregulated in AM following inflammatory stimuli
Francis et al., Innate Immun 2013 : In co-cultures of monocytes and PMN, mRNA expression of TGF-ß1 and MYD88 was up-regulated, and CD14 , TLR2 and IFN-? down-regulated with H. influenzae challenge